Bill Details
View committees (2)
View cosponsors (20)
- Rep. Fitzpatrick, Brian K. [R-Pennsylvania-1]
- Rep. Pettersen, Brittany [D-Colorado-7]
- Rep. Connolly, Gerald E. [D-Virginia-11]
- Rep. Tonko, Paul [D-New York-20]
- Rep. Cohen, Steve [D-Tennessee-9]
- Rep. Moulton, Seth [D-Massachusetts-6]
- Rep. Davis, Donald G. [D-North Carolina-1]
- Rep. Tenney, Claudia [R-New York-24]
- Rep. Miller, Carol D. [R-West Virginia-1]
- Rep. Johnson, Henry C. "Hank" [D-Georgia-4]
- Rep. Keating, William R. [D-Massachusetts-9]
- Rep. Houlahan, Chrissy [D-Pennsylvania-6]
- Rep. Deluzio, Christopher R. [D-Pennsylvania-17]
- Rep. Dingell, Debbie [D-Michigan-6]
- Rep. Obernolte, Jay [R-California-23]
- Rep. Trahan, Lori [D-Massachusetts-3]
- Rep. Tokuda, Jill N. [D-Hawaii-2]
- Rep. Harder, Josh [D-California-9]
- Rep. Jackson, Jonathan L. [D-Illinois-1]
- Rep. Wasserman Schultz, Debbie [D-Florida-25]
AI Summary This summary was generated by AI from the bill text. AI can get information wrong.
This bill would make it easier for people being treated for substance use disorder to get care through telehealth. It changes current drug law so that, for certain approved medications, a patient could qualify after one in-person medical visit and one telehealth visit instead of needing only in-person evaluation. The goal is to improve access to treatment, especially for people who have trouble reaching a doctor in person.
- It applies to controlled substances in schedule III, IV, or V that have been approved by the Food and Drug Administration to treat substance use disorder.
- Under the bill, a doctor or other qualified practitioner could use one telehealth evaluation as part of the required medical review before prescribing those medicines.
- The bill defines telehealth evaluation as a real-time medical visit done from a remote location using communication tools that allow two-way interaction, including audio-only or audio and video.
- The telehealth visit must follow all federal and state laws, and the practitioner must not be a pharmacist.
Official Summaries
Telehealth Response for E-prescribing Addiction Therapy Services Act or the TREATS Act
This bill permanently allows health care practitioners to prescribe certain controlled substances for treating substance use disorders via telehealth without evaluating the patient in person.
Generally, a health care practitioner may not prescribe a controlled substance via telehealth unless they first conduct an in-person medical evaluation. Federal regulations currently provide a temporary exception to this requirement, allowing practitioners to prescribe schedule II-V controlled substances for legitimate medical purposes (such as treating substance use disorders) via telehealth without an in-person evaluation. However, this temporary regulatory flexibility expires on December 31, 2025.
The bill permanently allows practitioners to prescribe schedule III-V controlled substances for the treatment of a substance use disorder via telehealth without conducting an in-person evaluation. In such instances, a practitioner may conduct a telehealth evaluation using audio-only or audio and video equipment.
Current Full Text
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1627 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 1627
To amend the Controlled Substances Act to allow for the use of
telehealth in substance use disorder treatment, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
February 26, 2025
Mr. Norcross (for himself and Mr. Fitzpatrick) introduced the following
bill; which was referred to the Committee on Energy and Commerce, and
in addition to the Committee on the Judiciary, for a period to be
subsequently determined by the Speaker, in each case for consideration
of such provisions as fall within the jurisdiction of the committee
concerned
_______________________________________________________________________
A BILL
To amend the Controlled Substances Act to allow for the use of
telehealth in substance use disorder treatment, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Telehealth Response for E-
prescribing Addiction Therapy Services Act'' or the ``TREATS Act''.
SEC. 2. TELEHEALTH FOR SUBSTANCE USE DISORDER TREATMENT.
Section 309(e)(2) of the Controlled Substances Act (21 U.S.C.
829(e)(2)) is amended--
(1) in subparagraph (A)(i)--
(A) by striking ``at least 1 in-person medical
evaluation'' and inserting the following: ``at least--
``(I) 1 in-person medical
evaluation''; and
(B) by adding at the end the following:
``(II) for purposes of prescribing
a controlled substance in schedule III,
IV, or V that has been approved by the
Food and Drug Administration for the
treatment of a substance use disorder,
1 telehealth evaluation of the patient;
or''; and
(2) by adding at the end the following:
``(D) The term `telehealth evaluation' means a
medical evaluation that is conducted in accordance with
applicable Federal and State laws by a practitioner
(other than a pharmacist) who is at a location remote
from the patient and is communicating with the patient,
or a practitioner who is treating the patient, using a
telecommunications system referred to in section
1834(m) of the Social Security Act (42 U.S.C. 1395m(m))
that includes audio-only or audio and video equipment
permitting two-way, real-time interactive communication
between the distant site practitioner and the patient,
or the practitioner who is treating the patient.''.
<all>